Patient advocates merit a voice in FDA drug reviews.

I am writing in response to the recent commentary criticizing patient advocacy groups for their involvement in the U.S. Food and Drug Administration’s approval of Relyvrio, a drug for ALS (“Patient advocacy groups should stay out of drug approvals,” May 10). While the commentary raises valid concerns about the FDA’s approval process and the drug’s…